Loading...
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Backen, Alison C Lopes, A Wasan, H Palmer, D Duggan, M Cunningham, D Anthoney, A Corrie, P Madhusudan, S Maraveyas, A
Backen, Alison C
Lopes, A
Wasan, H
Palmer, D
Duggan, M
Cunningham, D
Anthoney, A
Corrie, P
Madhusudan, S
Maraveyas, A
Citations
Altmetric:
Abstract
Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may improve patient outcomes.
Description
Date
2018-06-21
Publisher
Collections
Files
Keywords
Type
Article
Citation
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. 2018, Br J Cancer